Analysis of Advantages and Disadvantages of Modern Hypoglycemic Drugs

More alternatives for treating type 2 diabetes (T2DM) are provided by new hypoglycemic medications, such as sodium-glucose cotransporter 2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucagon-like peptide 1 receptor agonists (GLP-1RA). They are usually well tolerated, though occasionally care must be used. In prediabetes and type 2 diabetes, combination therapy with novel hypoglycemic medications has demonstrated satisfactory glucose control in clinical studies (mainly traditional stepwise therapy); however, early combination therapy seems to offer faster, greater, and longer-lasting advantages. Now that oral semaglutide is widely used in clinical settings, it's time to create combination medications that include novel hypoglycemic medications, particularly SGLT-2i and/or GLP-1RA, to reduce the risk of prediabetes, newly diagnosed type 2 diabetes, and its cardiovascular complications while increasing patient compliance. SGLT-2i protects against heart failure through both direct and indirect effects, according to preclinical and clinical research. More research is required to determine how this all-encompassing protective effect controls the dynamic alterations of cardiac genes. From the standpoint of "clinical drug-mechanism-intensive disease treatment," we offer suggestions for the creation of medications for heart failure. This will expedite the creation of medications for heart failure and, to some extent, direct their usage. Patients with type 2 diabetes who fast during Ramadan benefit clinically from the newer glucose-lowering drugs, according to this systematic review and meta-analysis.